Safinamide methanesulfonate

Safinamide methanesulfonate (CAS 202825-46-5) is a pharmaceutical-grade central nervous system drug ingredient manufactured directly by Polpharma in crystalline anhydrous Form A1, with samples available. It is a monoamine oxidase type B (MAO-B) inhibitor that extends dopamine activity in the brain, given together with levodopa and carbidopa to treat 'wearing-off' episodes of muscle stiffness and loss of muscle control in Parkinson's disease patients; note that in patent-protected markets such as Poland, the supplier states this product is developed only for regulatory/R&D purposes or export to non-EU countries under SPC exemption, not general sale. It is offered across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.